sing Alteplase as a clot lysis treatment from 4.5 to 9 hours on onset in Acute Ischemic Stroke patients
- Conditions
- Health Condition 1: G00-G99- Diseases of the nervous system
- Registration Number
- CTRI/2021/11/038340
- Lead Sponsor
- All India Institute Of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Age > 18 years
-Acute Ischemic Stroke symptom onset within past 4.5-9 hours
-Acute Ischemic Stroke consistent within ICA, MCA or ACA territory
-Baseline mRS 0-2
-NIHSS score of >5 at baseline and prior to
randomization
-Imaging eligibility with perfusion lesion ischemic core mismatch greater than 1.8 between
the volume of hypoperfusion and volume of the
ischemic core, an absolute difference in volume
greater than 10 ml, and an ischemic-core volume
of less than 70 ml
-Imaging shows more than 1/3 of MCA territory
infarct or more than one vascular territory
-Acute or previous intracranial hemorrhage
-Active internal organ bleeding
- Known hypersensitivity to Alteplase
- Seizures at stroke onset
-Severe, uncontrolled hypertension
- Treatment with a thrombolytic within last 3
months
-Prior ischemic stroke, severe head trauma,
intracranial/intraspinal injury within 3 months
-Gastrointestinal malignancy or GI bleed within
21 days
-Occlusion in > 1 vascular territory
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method